Cardiff Oncology Inc. (NASDAQ: CRDF)
$4.2000
-0.0600 ( -4.33% ) 415.4K
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").
Market Data
Open
$4.2000
Previous close
$4.2600
Volume
415.4K
Market cap
$278.07M
Day range
$4.1440 - $4.5240
52 week range
$1.4100 - $6.4200
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
ars | Annual reports | 1 | Apr 25, 2024 |
8-k | 8K-related | 16 | Apr 08, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
4 | Insider transactions | 1 | Mar 07, 2024 |
8-k | 8K-related | 55 | Feb 29, 2024 |
10-k | Annual reports | 77 | Feb 29, 2024 |
8-k | 8K-related | 78 | Jan 08, 2024 |
4 | Insider transactions | 1 | Dec 19, 2023 |